PCSK9
(Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
Type de proteíne
Recombinant
Attributs du protein
AA 31-692
Origine
Humain
Source
HEK-293 Cells
Purification/Conjugué
Cette PCSK9 protéine est marqué à la His tag.
Fonction
Human PCSK9 Protein
Séquence
Gln31-Gln692
Attributs du produit
Recombinant Human PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln31-Gln692.
Pureté
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Stérilité
0.22 μm filtered
niveau d'endotoxine
Less than 1EU per μg by the LAL method.
Biological Activity Comment
Immobilized Human PCSK9, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-PCSK9 antibody, hFc Tag with the EC50 of 0.16μg/ml determined by ELISA. The affinity constant of 0.35 nM as determined in SPR assay (Biacore T200). See testing image for detail.
PCSK9
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
Crystallography grade
PCSK9
Origine: Souris
Hôte: Cellules d'insectes
Recombinant
>95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot.
WB, SDS, ELISA, Crys
Restrictions
For Research Use only
Format
Liquid
Buffer
Supplied as 0.22μm filtered solution in 20 mM PB, 300 mM NaCl, 10 % Glycerol ( pH 7.4).
Stock
-80 °C
Stockage commentaire
Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Date de péremption
12 months
Antigène
PCSK9
(Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
FH3 Protein, HCHOLA3 Protein, LDLCQ1 Protein, NARC-1 Protein, NARC1 Protein, PC9 Protein, AI415265 Protein, AI747682 Protein, Narc1 Protein, proprotein convertase subtilisin/kexin type 9 Protein, proprotein convertase subtilisin/kexin type 9 L homeolog Protein, PCSK9 Protein, pcsk9.L Protein, pcsk9 Protein, Pcsk9 Protein
Sujet
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Poids moléculaire
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Tris-Bis PAGE result.